Optimization of anti-microbials in the treatment of Cystic Fibrosis Pulmonary Exacerbations:  II. Therapies for Allergic Bronchopulmonary Aspergillosis (ABPA).

Related Articles

Optimization of anti-microbials in the treatment of Cystic Fibrosis Pulmonary Exacerbations:  II. Therapies for Allergic Bronchopulmonary Aspergillosis (ABPA).

Pediatr Pulmonol. 2020 Sep 18;:

Authors: Epps QJ, Epps KL, Zobell JT, Young DC

Abstract
This review is the second article in the State-of-the-Art series and aims to evaluate medications used in the treatment of allergic bronchopulmonary aspergillosis (ABPA) in pediatric and adult patients with cystic fibrosis (CF). ABPA is one of several organisms that are found in the airways of CF patients. This review provides an evidence-based summary of pharmacokinetic/pharmacodynamic (PK/PD), tolerability, and efficacy studies of medications including corticosteroids, amphotericin B, azole anti-fungals (isavuconazole, itraconazole, posaconazole, and voriconazole), and a monoclonal antibody omalizumab in the treatment of ABPA and identifies areas where further study is warranted. This article is protected by copyright. All rights reserved.

PMID: 32946194 [PubMed - as supplied by publisher]